Intelligence Β· Clinical Pipeline

Denali Therapeutics Pipeline

All ClinicalTrials.gov programs at Denali Therapeutics β€” phase, modality, and trial IDs.

Programs
23

Quick answer

Denali Therapeutics has 23 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. BIIB122

    Denali Therapeutics

    Parkinson Disease

    phase 3 small molecule active

    2 trials
  2. DNL343

    Denali Therapeutics

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    2 trials
  3. Elaprase 2 mg/ml concentrate for solution for infusion

    Denali Therapeutics

    Mucopolysaccharidosis Type II [MPS II]

    phase 3 small molecule active

    1 trial
  4. tividenofusp alfa

    Denali Therapeutics

    Mucopolysaccharidosis II

    phase 3 small molecule active

    3 trials
  5. -, DNL593 Placebo, Sterile lyophilisate in single-dose glass vials, -, FAMOTIDINE

    Denali Therapeutics

    Frontotemporal Dementia (FTD)

    phase 2 small molecule active

    1 trial
  6. A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants with Hunter Syndrome

    Denali Therapeutics

    Hunter Syndrome (Mucopolysaccharidosis Type II [MPS II])

    phase 2 other active

    1 trial
  7. BIIB122 225 mg

    Denali Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial
  8. BIIB122, Placebo to BIIB122

    Denali Therapeutics

    Parkinson’s disease

    phase 2 small molecule active

    1 trial
  9. DNL126

    Denali Therapeutics

    Mucopolysaccharidosis Type IIIA

    phase 2 small molecule active

    1 trial
  10. DNL593

    Denali Therapeutics

    Frontotemporal Dementia

    phase 2 small molecule active

    1 trial
  11. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease

    Denali Therapeutics

    Early Alzheimer's Disease

    phase 1 other active

    1 trial
  12. BIIB122 (DNL151)

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  13. DNL151

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  14. DNL201

    Denali Therapeutics

    Parkinson Disease

    phase 1 small molecule completed

    1 trial
  15. DNL201

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  16. DNL343

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials
  17. DNL628

    Denali Therapeutics

    Alzheimer Disease, Early Onset

    phase 1 small molecule active

    1 trial
  18. DNL747

    Denali Therapeutics

    Amyotrophic Lateral Sclerosis

    phase 1 small molecule terminated

    1 trial
  19. DNL747

    Denali Therapeutics

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial
  20. DNL919

    Denali Therapeutics

    Healthy Participant

    phase 1 small molecule completed

    1 trial
  21. DNL952

    Denali Therapeutics

    Late-onset Pompe Disease

    phase 1 small molecule active

    1 trial
  22. [14C] BIIB122 ([14C] DNL151)

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial
  23. [14C]-DNL343

    Denali Therapeutics

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Denali Therapeutics have?

23 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources Β· All pipeline programs